The LXM.5 pilot study reveals an 80% bioavailability increase compared to competing products combining levodopa and carbidopa. The study additionally shows sustained and smooth levodopa levels in ...

Parkinson’s disease is a progressive neurodegenerative disorder that affects millions of people worldwide. In the United ...

A dopa decarboxylase inhibitor (DDCI), such as carbidopa or benserazide, is administered with levodopa to attenuate its peripheral conversion to dopamine, reduce nausea and increase central ...

[63] A second trial, called Stalevo Reduction in Dyskinesia Evaluation (STRIDE-PD), was designed to evaluate whether Stalevo would delay the onset of dyskinesia compared with levodopa/carbidopa.

It happens when levodopa/carbidopa’s effects wear off, or the drug isn’t working as it should. Nourianz can cause certain side effects, some more common than others. These side effects may be ...

This term refers to the sudden return of Parkinson’s disease symptoms between doses of carbidopa/levodopa (another drug often prescribed for Parkinson’s disease). Xadago helps decrease the ...